Visit https://www.peervoice.com/WVF860 to view the entire programme with slides. After completing “Managing Generalised Myasthenia Gravis: A Tale of Two Targets”, participants will be able to: Summarise the pathogenic contributors in generalised myasthenia gravis (gMG) and their role in disease progression; Translate the clinical data for emerging therapies for uncontrolled gMG in the context of current clinical practice; and Appraise how emerging therapies could evolve the standard of care for patients with uncontrolled gMG.